Phaseline

Targets › HRH1

HRH1 (Histamine H1 receptor): drug programs, companies and trials

29 programs from 27 companies in 34 trials: 18 Phase 2, 7 Phase 3, 6 Phase 1, 3 Phase 4; Immunology, Other, Neurology; next expected readout Nov 2026.

G protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter. Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. (UniProt, P35367)

Open in Phaseline: the race on HRH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kasr El Aini Hospitalchlorpheniramine
Histamine H1 receptor antagonist
HRH1Phase 4Blood Transfusion Associated Adverse ReactionsNov 2026
University of RochesterDiphenhydramine
Histamine H1 receptor antagonist
HRH1Phase 4PainFeb 2027
University of PennsylvaniaDiphenhydramine
Histamine H1 receptor antagonist
HRH1Phase 4InsomniaJan 2032
Second Affiliated Hospital, Zhejiang University, School of MedicineFexofenadine
Histamine H1 receptor antagonist
HRH1Phase 3Zhejiang University; ST-segment Elevation Myocardial Infarction (STEMI)Dec 2026
Craig A. Friesen, MDKetotifen
H1 receptor antagonist and mast cell stabilizer
HRH1Phase 3Functional DyspepsiaApr 2027
Florida Atlantic UniversityDiphenhydramine
Histamine H1 receptor antagonist
HRH1Phase 3Laceration of SkinJun 2027
Guy BoeckxstaensEbastine
Histamine 1 receptor antagonist
HRH1Phase 3IBS - Irritable Bowel SyndromeOct 2027
Shandong New Time PharmaceuticalCetirizine
Histamine H1 receptor antagonist
HRH1Phase 3Acute Urticaria–
Tanta UniversityKetotifen Oral Tablet
H1 receptor antagonist (antihistamine)
HRH1Phase 3Neuropathy;Peripheral–
Horus UniversityDesloratadine
Histamine H1 receptor antagonist
HRH1Phase 2Rheumatoid Arthritis (RA); Rheumatoid ArthritisNov 2026
AHS Cancer Control AlbertaLoratadine
Histamine H1 receptor antagonist
HRH1Phase 2Stem Cell Transplant ComplicationsDec 2026
Tanta UniversityFexofenadine
Histamine H1 receptor antagonist
HRH1Phase 2Parkinson DiseaseDec 2026
University of Illinois ChicagoClemastine Fumarate
Histamine H1 receptor antagonist
HRH1Phase 2DepressionDec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaChlorpheniramine
Histamine H1 receptor antagonist
HRH1Phase 2Allergic Transfusion ReactionDec 2026
Tanta Universitydesloratadine
Histamine H1 receptor antagonist
HRH1Phase 2Ulcerative Colitis (UC)Feb 2027
The University of Texas Health Science Center, HoustonDiphenhydramine
Histamine H1 receptor antagonist
HRH1Phase 2Labor DystociaMar 2027
University of California, San FranciscoClemastine fumarate
Histamine H1 receptor antagonist
HRH1Phase 2Optic Neuritis; Multiple Sclerosis (MS)Jun 2027
Val AdamsLoratadine
Histamine H1 receptor antagonist
HRH1Phase 2Solid TumorsJul 2027
Laval UniversityCyproheptadine
Histamine H1 receptor antagonist
HRH1Phase 2Ischemic Mitral RegurgitationSep 2027
Chuan QinTerfenadine
Histamine H1 receptor antagonist
HRH1Phase 2Relapsing Remitting Multiple SclerosisOct 2027
Stanford UniversityDiphenhydramine
Histamine H1 receptor antagonist
HRH1Phase 2AutismDec 2027
Montefiore Medical CenterDesloratadine
Histamine H1 receptor antagonist
HRH1Phase 2Breast CancerDec 2029
Sheba Medical CenterClemastine
Histamine H1 receptor antagonist
HRH1Phase 2Williams Syndrome–
Md. Hazrat Aliebastine
H1 receptor antagonist (antihistamine)
HRH1Phase 2Irritable Bowel Syndrome - Diarrhoea–
Bridget LaMonica Ostrem, M.D., Ph.D.Clemastine fumarate
Histamine H1 receptor antagonist
HRH1Phase 1White Matter InjuryApr 2028
University of Colorado, DenverClemastine Fumarate
Histamine H1 receptor antagonist
HRH1Phase 1Central Auditory Processing DisorderJul 2028
D. Walter WrayFexofenadine
Histamine H1 receptor antagonist
HRH1Phase 1Chronic Obstructive Pulmonary DiseaseAug 2030
October 6 UniversityFexofenadine
Histamine H1 receptor antagonist
HRH1Phase 1Rheumatoid Arthritis–
Noucor HealthRupatadine
Platelet activating factor receptor antagonist; Histamine H1 receptor antagonist
PTAFR, HRH1Phase 1Renal Impairment; Rheumatoid Arthritis; Ulcerative Colitis–

Conditions

Rheumatoid Arthritis (3) IBS - Irritable Bowel Syndrome (1) Central Auditory Processing Disorder (1) Labor Dystocia (1) Insomnia (1) Acute Urticaria (1) Chronic Obstructive Pulmonary Disease (1) Parkinson Disease (1) Solid Tumors (1) Ulcerative Colitis (UC) (1) Ischemic Mitral Regurgitation (1) Depression (1)

Modalities

small molecule (28), mixed (1)

Companies

Tanta University (3) Guy Boeckxstaens (1) October 6 University (1) University of Colorado, Denver (1) The University of Texas Health Science Center, Houston (1) University of Pennsylvania (1) Shandong New Time Pharmaceutical (1) D. Walter Wray (1) Val Adams (1) Laval University (1) University of Illinois Chicago (1) Institute of Hematology & Blood Diseases Hospital, China (1) Stanford University (1) Bridget LaMonica Ostrem, M.D., Ph.D. (1) Md. Hazrat Ali (1) Kasr El Aini Hospital (1) AHS Cancer Control Alberta (1) Noucor Health (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) University of California, San Francisco (1)

Related targets

PTAFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.